Also known as Nitoman and Xenazine
Tetrabenazine is a drug for the symptomatic treatment of hyperkinetic movement disorder and is marketed under the trade names Nitoman in Canada and Xenazine in New Zealand and some parts of Europe, and is also available in the USA as an orphan drug. On August 15, 2008 the U.S. Food and Drug Administration (FDA) approved the use of tetrabenazine to treat chorea associated with Huntington's disease (HD), the first in the US. The compound has been known since the 1950s. The effort for US FDA approval was led by Dr. Joseph Jankovic. According to a 2008 news report, "Americans with Huntington's who weren't Jankovic's patients ordered tetrabenazine from Canada if they could afford it. But the worsening exchange rate put the price out of reach for many. A recent check found Canadian Internet pharmacies selling generic 25-milligram pills for $1.75 or more each in U.S. currency, brand-name 25-mg pills for around $2.35 each." After the FDA approval, Dr. Jancovic said "I'm worried that the drug is just going to be too expensive" and initial pricing was $68.50 per 25 mg tablet.Source: Wikipedia
Estimated Total Cost: $3942.15 for an average of 28 days supply
Patients are most commonly prescribed tetrabenazine to treat blastomycosis, rabies, west nile virus, and pick disease.
Patients taking tetrabenazine most commonly experience side effects like restlessness.